GlaxoSmithKline Pharmaceuticals Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹2454.80
Market cap
41,587 Cr
Stock P/E
36.9
P/B
18.20
Dividend yield
1.7%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 762 Cr | 1,719 Cr | 2,524 Cr | 3,454 Cr | 815 Cr | 1,825 Cr | 949 Cr | 974 Cr | 805 Cr | 980 Cr | 1,041 Cr | 995 Cr |
| Operating expenses (approx.) | 564 Cr | 1,203 Cr | 1,926 Cr | 2,566 Cr | 548 Cr | 1,198 Cr | 622 Cr | 601 Cr | 510 Cr | 608 Cr | 620 Cr | 608 Cr |
| EBITDA | 198 Cr | 515 Cr | 598 Cr | 888 Cr | 266 Cr | 627 Cr | 327 Cr | 374 Cr | 295 Cr | 372 Cr | 421 Cr | 387 Cr |
| OPM % | 25.9% | 30.0% | 23.7% | 25.7% | 32.7% | 34.4% | 34.4% | 38.4% | 36.6% | 38.0% | 40.5% | 38.9% |
| Other income | 36 Cr | 65 Cr | 93 Cr | 123 Cr | 36 Cr | 70 Cr | 35 Cr | 41 Cr | 44 Cr | 34 Cr | 32 Cr | 36 Cr |
| Interest | 0.28 Cr | 0.71 Cr | 1 Cr | 2 Cr | 0.37 Cr | 0.64 Cr | 0.09 Cr | 0.58 Cr | 0.42 Cr | 0.51 Cr | 1 Cr | 0.61 Cr |
| Depreciation | 16 Cr | 34 Cr | 52 Cr | 70 Cr | 16 Cr | 33 Cr | 19 Cr | 15 Cr | 16 Cr | 17 Cr | 20 Cr | 13 Cr |
| Profit before tax | 181 Cr | 480 Cr | 546 Cr | 816 Cr | 249 Cr | 593 Cr | 308 Cr | 359 Cr | 279 Cr | 354 Cr | 400 Cr | 373 Cr |
| Tax % | 26.9% | 27.2% | 27.5% | 27.7% | 26.9% | 26.7% | 25.4% | 26.7% | 26.5% | 27.3% | 26.1% | 25.5% |
| Net profit | 132 Cr | 350 Cr | 395 Cr | 590 Cr | 182 Cr | 435 Cr | 230 Cr | 263 Cr | 205 Cr | 257 Cr | 296 Cr | 278 Cr |
| EPS (₹) | ₹7.04 | ₹20.65 | ₹29.77 | ₹34.83 | ₹10.76 | ₹25.43 | ₹13.57 | ₹15.52 | ₹12.10 | ₹15.07 | ₹16.54 | ₹16.40 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,128 Cr | 3,224 Cr | 3,199 Cr | 3,278 Cr | 3,252 Cr | 3,454 Cr | 3,749 Cr | 3,822 Cr | Sign in for TTM |
| Operating expenses (approx.) | 2,396 Cr | 2,830 Cr | 2,566 Cr | 2,429 Cr | 2,448 Cr | 2,689 Cr | 2,421 Cr | 2,346 Cr | Sign in for TTM |
| EBITDA | 732 Cr | 395 Cr | 633 Cr | 849 Cr | 803 Cr | 765 Cr | 1,328 Cr | 1,475 Cr | Sign in for TTM |
| OPM % | 23.4% | 12.2% | 19.8% | 25.9% | 24.7% | 22.2% | 35.4% | 38.6% | Sign in for TTM |
| Other income | 102 Cr | 79 Cr | 111 Cr | 76 Cr | 101 Cr | 123 Cr | 146 Cr | 145 Cr | Sign in for TTM |
| Interest | 0.55 Cr | 6 Cr | 4 Cr | 2 Cr | 2 Cr | 2 Cr | 1 Cr | 3 Cr | Sign in for TTM |
| Depreciation | 49 Cr | 83 Cr | 79 Cr | 68 Cr | 66 Cr | 70 Cr | 67 Cr | 66 Cr | Sign in for TTM |
| Profit before tax | 683 Cr | 306 Cr | 551 Cr | 779 Cr | 836 Cr | 816 Cr | 1,260 Cr | 1,406 Cr | Sign in for TTM |
| Tax % | 34.8% | 69.5% | 34.9% | 51.1% | 27.4% | 27.7% | 26.4% | 26.3% | Sign in for TTM |
| Net profit | 445 Cr | 93 Cr | 358 Cr | 1,695 Cr | 611 Cr | 590 Cr | 928 Cr | 1,036 Cr | Sign in for TTM |
| EPS (₹) | ₹26.29 | ₹5.50 | ₹21.14 | ₹100.04 | ₹36.05 | ₹34.83 | ₹54.52 | ₹54.52 | Sign in for TTM |
| Dividend payout % | — | — | — | 29.9% | 249.8% | 91.8% | 80.8% | 68.9% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 169 Cr | 169 Cr | 169 Cr | 169 Cr | 169 Cr | 169 Cr | 169 Cr | 169 Cr |
| Reserves | 1,970 Cr | 1,651 Cr | 1,330 Cr | 0.0000 Cr | 1,572 Cr | 1,608 Cr | 1,782 Cr | 2,115 Cr |
| Borrowings | 0.18 Cr | 0.02 Cr | — | — | — | — | — | — |
| Other liabilities | 1,767 Cr | 1,294 Cr | 1,578 Cr | 1,945 Cr | 1,585 Cr | 1,779 Cr | 2,157 Cr | 2,039 Cr |
| Total liabilities | 3,909 Cr | 3,134 Cr | 3,096 Cr | 4,623 Cr | 3,327 Cr | 3,557 Cr | 4,108 Cr | 4,324 Cr |
| Fixed assets (net) | 364 Cr | 707 Cr | 341 Cr | 295 Cr | 295 Cr | 297 Cr | 270 Cr | 274 Cr |
| CWIP | 1,003 Cr | 120 Cr | 13 Cr | 31 Cr | 20 Cr | 14 Cr | 14 Cr | 33 Cr |
| Investments | 25 Cr | 24 Cr | 24 Cr | 390 Cr | 518 Cr | 813 Cr | 1,118 Cr | 1,391 Cr |
| Other assets | 1,988 Cr | 2,062 Cr | 2,333 Cr | 3,863 Cr | 2,708 Cr | 3,012 Cr | 3,606 Cr | 3,785 Cr |
| Total assets | 3,909 Cr | 3,134 Cr | 3,096 Cr | 4,623 Cr | 3,327 Cr | 3,557 Cr | 4,108 Cr | 4,324 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 811 Cr | 484 Cr | 582 Cr | 1,290 Cr | 903 Cr |
| Cash from investing | — | — | — | -405 Cr | 808 Cr | 9 Cr | -46 Cr | 397 Cr |
| Cash from financing | — | — | — | -524 Cr | -1,543 Cr | -561 Cr | -769 Cr | -737 Cr |
| Net cash flow | — | — | — | -119 Cr | -251 Cr | 29 Cr | 475 Cr | 563 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 776 Cr | 440 Cr | 551 Cr | 1,267 Cr | 848 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 31.9% | 17.1% | 37.0% | 461.0% | 42.4% | 39.1% | 64.6% | 61.7% |
| ROE % | 20.6% | 5.1% | 23.9% | 0.0% | 35.1% | 33.2% | 0.0% | 45.3% |
| Debtor days | 14 | 11 | 25 | 23 | 22 | 23 | — | — |
| Inventory days | 260 | 372 | 421 | 338 | 392 | 352 | 351 | 382 |
| Days payable | 215 | 273 | 359 | 360 | 364 | 419 | — | — |
| Cash conversion cycle | 59 | 110 | 87 | 1 | 49 | -44 | 351 | 382 |
| Debt / equity | 0.00 | 0.0000 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
| Current ratio | 1.37 | 2.05 | 1.80 | 2.31 | 2.04 | 1.98 | 1.89 | 2.13 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 | -0.08 | -0.41 | -0.75 |
Compare with peers
Loading peers…